硫酸地贝卡星 | 58580-55-5

• 物质功能分类: 原料药 - 抗生素类药物 - 氨基糖苷类药
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 硫酸地贝卡星
• 中文别名: 地贝卡星硫酸盐
• 英文名称: Dibekacin sulfate
• 英文别名: (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid
• CAS: 58580-55-5；64070-13-9
• 化学式: C₁₈H₃₇N₅O₈*H₂O₄S
• 分子量: 549.6
• InChiKey: GXKUKBCVZHBTJW-USXQJGOZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.92
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  331
• 氢给体数：
  11
• 氢受体数：
  17

反应信息

• 作为反应物：
  描述：

  硫酸地贝卡星 、 alkaline earth salt of/the/ methylsulfuric acid 在 aminoglycoside 3-acetyltransferase (AAC⁽³⁾) 作用下， 以 phosphate buffer 为溶剂， 生成 3-N-acetyldibekacin
  参考文献：
  名称：

  Double Stage Activity in Aminoglycoside Antibiotics.

  摘要：

  对十四种不同的氨基糖苷类抗生素（AGs）进行实验，挑战来源于放线菌的氨基糖苷乙酰转移酶（AACs），以检验其“二重活性”，该活性被任意定义为在酶修饰后仍能保留的抗生素活性。在测试的庆大霉素（KM）类AGs中 [KM、双贝卡霉素（DKB）、阿米卡星和阿尔贝卡星（ABK）]，阿尔贝卡星在AAC(3)、AAC(2') 和 AAC(6') 乙酰化后仍保留活性。双贝卡霉素在AAC(2') 乙酰化后也保留了微弱的活性。在测试的庆大霉素（GM）类AGs中 [GM、微诺霉素、硫杉霉素（SISO）、耐替米星（NTL）和异帕霉素]，庆大霉素、硫杉霉素和耐替米星在AAC(2') 乙酰化后保留了活性。在测试的新霉素（NM）类AGs中 [利博霉素、新霉素、帕罗霉素]，新霉素在AAC(6') 和 AAC(2') 乙酰化后保留了活性。测试的阿斯霉素（ASTM）类AGs（ASTM和依斯塔霉素B）在AAC(2') 和 AAC(6') 乙酰化后均未保留活性。经过AAC(3) 和 AAC(2') 乙酰化的阿尔贝卡星衍生物的活性明显高于其他。含有克隆aac基因的放线菌利维丹斯TK21对在乙酰化后仍能保留活性的AGs表现出显著敏感，表明“二重活性”具有显著效果。

  DOI：

  10.7164/antibiotics.53.1168

文献信息

• GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY
  申请人：Cai Jianfeng

  公开号：US20150274782A1

  公开（公告）日：2015-10-01

  The present invention is directed to a novel class of antimicrobial agents called γ-AApeptides. The current invention provides various categories of γ-AApeptides, for example, linear γ-AApeptides, cyclic γ-AApeptides, and lipidated γ-AApeptides. γ-AApeptides of the current invention are designed to exert antimicrobial activity while being stable and non-toxic. γ-AApeptides also do not appear to lead to the development of microbial resistance in treated microorganisms. Thus, the disclosed γ-AApeptides can be used for the treatment of various medical conditions associated with pathogenic microorganisms.

  本发明涉及一种新型类别的抗微生物药物，称为γ-AA肽。当前发明提供了各种类别的γ-AA肽，例如线性γ-AA肽、环状γ-AA肽和脂质化γ-AA肽。本发明的γ-AA肽被设计为具有抗微生物活性，同时稳定且无毒。γ-AA肽似乎也不会导致被治疗微生物体内微生物产生抗药性。因此，所披露的γ-AA肽可用于治疗与病原微生物相关的各种医疗状况。
• External preparation for skin diseases containing nitroimidazole
  申请人：——

  公开号：US20030092754A1

  公开（公告）日：2003-05-15

  An external preparation for skin disease which comprises a nitroimidazole derivative represented by the following formula (I): 1 wherein R 1 , R 3 and R 4 may be the same or different and represent a hydrogen atom, a nitro group, a lower alkyl group, a substituted lower alkyl group, a lower alkenyl group, or a substituted lower alkenyl group; and R 2 represents a hydrogen atom, a lower alkyl group, a substituted lower alkyl group and a lower alkenyl group or a substituted lower alkenyl group, provided that any one of R 1 , R 3 and R 4 is a nitro group.

  一种外用制剂，用于皮肤疾病，包括以下式(I)所代表的硝基咪唑衍生物：1其中R1、R3和R4可以相同也可以不同，并表示氢原子、硝基、低烷基、取代的低烷基、低烯基或取代的低烯基；R2表示氢原子、低烷基、取代的低烷基和低烯基或取代的低烯基，只要R1、R3和R4中的任何一个是硝基。
• AZITHROMYCIN-CONTAINING AQUEOUS PHARMACEUTICAL COMPOSITION AND A METHOD FOR THE PREPARATION OF THE SAME
  申请人：SUZUKI Hidekazu

  公开号：US20070087980A1

  公开（公告）日：2007-04-19

  The invention provides an azithromycin-containing aqueous pharmaceutical composition, which comprises at least one member selected from the group consisting of azithromycin, its anhydride, its hydrate, and pharmaceutically acceptable salts thereof, and at least one member selected from the group consisting of monoethanolamine, diethanolamine, triethanolamine, amino acid, ethylenediaminetetraacetic acid, and pharmaceutically acceptable salts thereof, and which does not comprise boric acid or pharmaceutically acceptable salts thereof, and a method for the preparation of the composition, wherein an azithromycin-containing liquid is maintained at pH of 4.0 or higher throughout the method for the preparation. The composition has good heat and storage stability.

  本发明提供一种含有阿奇霉素的水性制药组合物，包括从以下组中选择的至少一种成员：阿奇霉素、其无水物、其水合物和其药学上可接受的盐，以及从以下组中选择的至少一种成员：单乙醇胺、双乙醇胺、三乙醇胺、氨基酸、乙二胺四乙酸和药学上可接受的盐，且不含硼酸或其药学上可接受的盐。本发明还提供一种制备该组合物的方法，其中阿奇霉素含液在制备过程中的pH值保持在4.0或更高。该组合物具有良好的热稳定性和储存稳定性。
• AMINOGLYCOSIDE DOSING REGIMENS
  申请人：Bruss Jon B.

  公开号：US20120208781A1

  公开（公告）日：2012-08-16

  The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections.

  本发明提供了新的氨基糖苷类药物给药方案，与增强微生物杀灭活性和降低肾毒性有关，并提供了使用这些给药方案治疗各种细菌感染的方法。
• The Novel Enzymatic 3"-N-Acetylation of Arbekacin by an Aminoglycoside 3-N-Acetyltransferase of Streptomyces Origin and the Resulting Activity.
  作者：KUNIMOTO HOTTA、ATSUKO SUNADA、JUN ISHIKAWA、SATOSHI MIZUNO、YOKO IKEDA、SHINICHI KONDO

  DOI：10.7164/antibiotics.51.735

  日期：——

  Kanamycin group antibiotics were subjected to enzymatic acetylation by a cell free extract containing an aminoglycoside 3-N-acetyltransferase, AAC(3)-X, derived from Streptomyces griseus SS-1198PR. Characterization of the incubated reaction mixtures by TLC and antibiotic assay revealed that a product retaining activity was specifically formed from arbekacin, an anti-MRSA semisynthetic aminoglycoside. The structural determination demonstrated that acetylation occurred at the 3″-amino group in arbekacin and amikacin, and at the 3-amino group in dibekacin as in the case of kanamycin. These results should reflected the effect of the (S)-4-amino-2-hydroxybutyryl side chain which is present in arbekacin and amikacin, but absent in dibekacin and kanamycin. The 3″-N-acetylation is the first finding in the enzymatic modifications of aminoglycoside antibiotics. 3″-N-Acetylarbekacin showed antibiotic activity as high as that of 2′-N-acetylarbekacin reported previously, whereas 3″-N-acetylamikacin showed no substantial activity. Thus, our results illuminated a novel aspect of arbekacin distinct from the other aminoglycosides.

  卡那霉素类抗生素通过一种不含细胞的提取物进行酶促乙酰化，该提取物含有一种来自灰链霉菌SS-1198PR的氨基糖苷3-N-乙酰转移酶AAC(3)-X。通过薄层色谱法和抗生素检测对反应混合物进行表征，结果表明，一种保留活性的产物是由阿贝卡星（一种抗MRSA的半合成氨基糖苷）特异性形成的。结构测定表明，乙酰化发生在阿贝卡星和阿米卡星的3″-氨基上，以及迪贝卡星的3-氨基上，就像卡那霉素的情况一样。这些结果应反映了阿贝卡星和阿米卡星中存在的（S）-4-氨基-2-羟基丁酰侧链的作用，而迪贝卡星和卡那霉素中则不存在这种作用。3″-N-乙酰化是氨基糖苷类抗生素酶促修饰的第一个发现。3″-N-乙酰化阿贝卡星显示出与之前报道的2′-N-乙酰化阿贝卡星相同的抗生素活性，而3″-N-乙酰化阿米卡星则没有表现出实质性的活性。因此，我们的结果揭示了阿贝卡星不同于其他氨基糖苷类药物的新特性。